MedPath

Prevalence of NAFLD in T2DM Patients

Not Applicable
Active, not recruiting
Conditions
Type 2 Diabetes
Fatty Liver, Nonalcoholic
T2D
NAFLD
Interventions
Diagnostic Test: FibroScan
Registration Number
NCT06445335
Lead Sponsor
Ziekenhuis Oost-Limburg
Brief Summary

To determine the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM).

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
385
Inclusion Criteria
  • ≥ 18 years of age
  • Having type 2 diabetes mellitus (T2DM)
  • Written informed consent obtained
Exclusion Criteria
  • Excessive alcohol use
  • Exclusion of other causes of liver disease and secondary causes of steatosis

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
FibroScanFibroScan-
Primary Outcome Measures
NameTimeMethod
Prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patientsBaseline

To determine the prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients followed at the department of Endocrinology in Ziekenhuis Oost-Limburg (ZOL), Genk, Belgium by means of FibroScan measurements.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ziekenhuis Oost-Limburg

🇧🇪

Genk, Limburg, Belgium

© Copyright 2025. All Rights Reserved by MedPath